纯度 | >90%SDS-PAGE. |
种属 | E.coli |
靶点 | rgpA |
Uniprot No | P28784 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 228-720aa |
氨基酸序列 | YTPVEEKQNGRMIVIVAKKYEGDIKDFVDWKNQRGLRTEVKVAEDIASPVTANAIQQFVKQEYEKEGNDLTYVLLVGDHKDIPAKITPGIKSDQVYGQIVGNDHYNEVFIGRFSCESKEDLKTQIDRTIHYERNITTEDKWLGQALCIASAEGGPSADNGESDIQHENVIANLLTQYGYTKIIKCYDPGVTPKNIIDAFNGGISLVNYTGHGSETAWGTSHFGTTHVKQLTNSNQLPFIFDVACVNGDFLFSMPCFAEALMRAQKDGKPTGTVAIIASTINQSWASPMRGQDEMNEILCEKHPNNIKRTFGGVTMNGMFAMVEKYKKDGEKMLDTWTVFGDPSLLVRTLVPTKMQVTAPAQINLTDASVNVSCDYNGAIATISANGKMFGSAVVENGTATINLTGLTNESTLTLTVVGYNKETVIKTINTNGEPNPYQPVSNLTATTQGQKVTLKWDAPSTKTNATTNTARSVDGIRELVLLSVSDAPELLRS |
预测分子量 | 56.0 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Cloning and expression of the rgpA gene from Porphyromonas gingivalis"**
*作者:Nakayama K. et al.*
摘要:该研究克隆了牙龈卟啉单胞菌的rgpA基因,并在大肠杆菌中成功表达重组RgpA蛋白酶,证实其具有精氨酸特异性蛋白水解活性,为后续酶学及致病机制研究奠定基础。
2. **"Recombinant RgpA protease induces pro-inflammatory cytokine release in human gingival fibroblasts"**
*作者:Guan S.M. et al.*
摘要:通过纯化重组RgpA蛋白,证明其能激活人牙龈成纤维细胞的NF-κB通路,促进IL-6和TNF-α分泌,提示其在牙周炎炎症反应中的关键作用。
3. **"Structural and functional characterization of the hemagglutinin domain of recombinant RgpA"**
*作者:O'Brien-Simpson N.M. et al.*
摘要:解析重组RgpA的血凝素结构域(HA-domains),揭示其介导细菌黏附宿主细胞及红细胞凝集的功能,为开发靶向抑制剂提供结构依据。
4. **"Immunization with recombinant RgpA domains protects against P. gingivalis-induced periodontitis in mice"**
*作者:Pathirana R.D. et al.*
摘要:在小鼠模型中,重组RgpA的免疫原性片段可诱导特异性抗体,显著降低牙槽骨吸收,验证其作为牙周病疫苗候选抗原的潜力。
**Background of rgpA Recombinant Protein**
The rgpA (Arg-gingipain A) recombinant protein is derived from *Porphyromonas gingivalis*, a keystone pathogen associated with chronic periodontitis, a severe inflammatory gum disease. As a cysteine protease, rgpA plays a critical role in the virulence of *P. gingivalis*, contributing to tissue destruction, immune evasion, and dysregulation of host inflammatory responses. The protein consists of a catalytic domain responsible for proteolytic activity and hemagglutinin/adhesion domains that facilitate bacterial adherence to host tissues and biofilm formation.
Recombinant rgpA is produced using genetic engineering techniques, often expressed in *Escherichia coli* or eukaryotic systems to ensure proper folding and post-translational modifications. Its production enables detailed study of its enzymatic mechanisms, interactions with host proteins (e.g., degradation of immunoglobulins, complement proteins, and cytokines), and its role in periodontal pathogenesis. Researchers also utilize rgpA to develop inhibitors or vaccines targeting *P. gingivalis* virulence, aiming to mitigate periodontitis and its systemic links to conditions like cardiovascular disease and diabetes.
Despite its utility, challenges remain in maintaining the protein’s native conformation and activity *in vitro*, requiring optimized expression and purification strategies. Current studies focus on structural analysis, substrate specificity, and therapeutic applications, positioning rgpA recombinant protein as a vital tool in both basic research and translational dentistry.
×